Agios Pharmaceuticals Inc Investor Event to Review Data Presented at ASH Transcript
All right, great. We're going to get started. So good evening and welcome, everyone. Thank you for joining us at the tail end of what's been an exciting and kind of long conference for some of us.
Before we begin, I do want to let you know that Jackie wishes she could be here. But as some of you know, several weeks ago, she had a hip replacement surgery. We felt like walking around the conference in Orlando, probably wasn't a good path to recovery. So I think I did 3 miles today before 10 a.m. So anyway, she's looking forward to seeing you all in San Francisco next month.
So here's our forward-looking statements disclaimer. As you know, those are subject to risks and uncertainties, which are outlined in our SEC filings. I'll start by giving you a bit of an overview. I'll provide some opening remarks on where we are on some of our corporate milestones, and then I'll turn it over to Chris to walk through some of the IDH data that we presented at the conference, and then we're lucky to have Dr. Eduard van Beers here to talk to us about the DRIVE PK data that we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
